Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Gudrun Goßrau; Stefanie Förderreuther; Ruth Ruscheweyh; Victoria Ruschil; Till Sprenger; David Lewis; Katharina Kamm; Tobias Freilinger; Lars Neeb; Volker Malzacher; Uwe Meier; Klaus Gehring; Torsten Kraya; Thomas Dresler; Christoph J. Schankin; Andreas R. Gantenbein; Gregor Brössner; Karin Zebenholzer; Hans Christoph Diener; Charly Gaul; Tim P. Jürgens

doi:10.1007/s00115-022-01403-1

Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Translated title of the contribution: Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis

Gudrun Goßrau
, Stefanie Förderreuther
, Ruth Ruscheweyh
, Victoria Ruschil
, Till Sprenger
, David Lewis
, Katharina Kamm
, Tobias Freilinger
, Lars Neeb
, Volker Malzacher
, Uwe Meier
, Klaus Gehring
, Torsten Kraya
, Thomas Dresler
, Christoph J. Schankin
, Andreas R. Gantenbein
, Gregor Brössner
, Karin Zebenholzer
, Hans Christoph Diener
, Charly Gaul

Tim P. Jürgens

Technischen Universität Dresden
Ludwig-Maximilians-Universität München
Deutsche Migräne- und Kopfschmerzgesellschaft
Technical University of Munich
Universitätsklinikum Tübingen
Deutsche Klinik für Diagnostik
LEWIS Neurologie
Klinikum Passau
Helios Global Health
Charité – Universitätsmedizin Berlin
Neurozentrum Reutlingen
Berufsverband Deutscher Neurologen
Berufsverband Deutscher Nervenärzte
Krankenhaus Sankt Georg Leipzig
Universitätsklinikum Halle-Saale
Tübingen
Inselspital Universitatsspital
ZURZACH Care
Praxis Neurologie am Untertor
Universitätsklinik für Neurologie
Medical University of Vienna
University Medicine Essen
Kopfschmerzzentrum Frankfurt
Rostock University Medical Center
KMG Krankenhaus Güstrow

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

Translated title of the contribution	Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis
Original language	German
Pages (from-to)	306-317
Number of pages	12
Journal	Nervenarzt
Volume	94
Issue number	4
DOIs	https://doi.org/10.1007/s00115-022-01403-1
State	Published - Apr 2023
Externally published	Yes

Access to Document

10.1007/s00115-022-01403-1

Cite this

Goßrau, G., Förderreuther, S., Ruscheweyh, R., Ruschil, V., Sprenger, T., Lewis, D., Kamm, K., Freilinger, T., Neeb, L., Malzacher, V., Meier, U., Gehring, K., Kraya, T., Dresler, T., Schankin, C. J., Gantenbein, A. R., Brössner, G., Zebenholzer, K., Diener, H. C., ... Jürgens, T. P. (2023). Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe. Nervenarzt, 94(4), 306-317. https://doi.org/10.1007/s00115-022-01403-1

@article{fd3518d021a64323aabf444f7df05dbb,

title = "Konsensusstatement der Migr{\"a}ne- und Kopfschmerzgesellschaften (DMKG, {\"O}KSG \& SKG) zur Therapiedauer der medikament{\"o}sen Migr{\"a}neprophylaxe",

abstract = "Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society ({\"O}KSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.",

keywords = "Migraine, Migraine disorder, Migraine headache, Migraine therapy, Therapy guideline",

author = "Gudrun Go{\ss}rau and Stefanie F{\"o}rderreuther and Ruth Ruscheweyh and Victoria Ruschil and Till Sprenger and David Lewis and Katharina Kamm and Tobias Freilinger and Lars Neeb and Volker Malzacher and Uwe Meier and Klaus Gehring and Torsten Kraya and Thomas Dresler and Schankin, \{Christoph J.\} and Gantenbein, \{Andreas R.\} and Gregor Br{\"o}ssner and Karin Zebenholzer and Diener, \{Hans Christoph\} and Charly Gaul and J{\"u}rgens, \{Tim P.\}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2023",

month = apr,

doi = "10.1007/s00115-022-01403-1",

language = "Deutsch",

volume = "94",

pages = "306--317",

journal = "Nervenarzt",

issn = "0028-2804",

publisher = "Springer Medizin",

number = "4",

}

Goßrau, G, Förderreuther, S, Ruscheweyh, R, Ruschil, V, Sprenger, T, Lewis, D, Kamm, K, Freilinger, T, Neeb, L, Malzacher, V, Meier, U, Gehring, K, Kraya, T, Dresler, T, Schankin, CJ, Gantenbein, AR, Brössner, G, Zebenholzer, K, Diener, HC, Gaul, C & Jürgens, TP 2023, 'Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe', Nervenarzt, vol. 94, no. 4, pp. 306-317. https://doi.org/10.1007/s00115-022-01403-1

TY - JOUR

T1 - Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

AU - Goßrau, Gudrun

AU - Förderreuther, Stefanie

AU - Ruscheweyh, Ruth

AU - Ruschil, Victoria

AU - Sprenger, Till

AU - Lewis, David

AU - Kamm, Katharina

AU - Freilinger, Tobias

AU - Neeb, Lars

AU - Malzacher, Volker

AU - Meier, Uwe

AU - Gehring, Klaus

AU - Kraya, Torsten

AU - Dresler, Thomas

AU - Schankin, Christoph J.

AU - Gantenbein, Andreas R.

AU - Brössner, Gregor

AU - Zebenholzer, Karin

AU - Diener, Hans Christoph

AU - Gaul, Charly

AU - Jürgens, Tim P.

PY - 2023/4

Y1 - 2023/4

N2 - Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

AB - Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

KW - Migraine

KW - Migraine disorder

KW - Migraine headache

KW - Migraine therapy

KW - Therapy guideline

UR - https://www.scopus.com/pages/publications/85140982277

U2 - 10.1007/s00115-022-01403-1

DO - 10.1007/s00115-022-01403-1

M3 - Übersichtsartikel

C2 - 36287216

AN - SCOPUS:85140982277

SN - 0028-2804

VL - 94

SP - 306

EP - 317

JO - Nervenarzt

JF - Nervenarzt

IS - 4

ER -

Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Abstract

Access to Document

Other files and links

Fingerprint

Cite this